This large-scale pan-cancer study of nearly 69,000 tumor-normal pairs profiled by MSK-IMPACT characterizes the biological and clinical implications of SMARCA4 alterations across functional mutation classes and allelic configurations. SMARCA4 alterations were most frequently observed in thymic epithelial tumors (10.7%), non-small cell lung cancer (7.1%), bladder cancer (5.6%), and cervical cancer (5%). Distinct profiles of genomic complexity, co-mutations, and mutational signatures were associated with specific allelic states (monoallelic vs. biallelic) and mutation classes (class 1 vs. class 2). Preliminary data from a phase I trial of the BRM degrader PRT3789 revealed clinical benefit, including one complete response, among patients harboring monoallelic class 2 SMARCA4 alterations with preserved BRG1 expression.
The innovaTV 204 study evaluated tisotumab vedotin (TV), a tissue factor (TF)-targeting antibody-drug conjugate, in patients with recurrent or metastatic cervical cancer. Although TF expression is required for TV binding, clinical responses were found to be independent of TF levels. This analysis revealed that higher expression of gene signatures linked to natural killer (NK) cells and myeloid cells was associated with improved clinical outcomes. In vitro studies confirmed that TV induces tumor cell death through myeloid-mediated ADCP and NK-mediated ADCC mechanisms, irrespective of TF levels. These findings suggest a multimodal mechanism of action for TV, involving both direct cytotoxicity and immune effector-mediated effects.
Cervical adenocarcinoma is linked to poorer survival and reduced response to immunotherapy. This study identified STK11 alterations, including mutations and focal deletions, as a distinct feature of HPV-positive cervical adenocarcinomas, affecting 23% of these tumors. These alterations are associated with a younger age at diagnosis, poorer overall survival, and inferior outcomes following immune checkpoint inhibitor therapy. Comprehensive genomic analyses revealed complex structural rearrangements involving chromosome 19p and STK11. These findings define an aggressive molecular subgroup and have implications for molecular classification and future targeted therapeutic strategies.
This study investigated the functional impact of recurrent mutations in cervical cancer. Using whole-exome sequencing, cell models, and in vivo experiments, researchers identified the PIK3CA-E545K mutation as frequently occurring. This specific mutation was shown to enhance tumor cell proliferation and invasion while suppressing apoptosis. These effects are mediated by sustained activation of the AKT/mTOR signaling pathway. The findings suggest that targeting the PI3K/AKT/mTOR axis could represent a promising therapeutic strategy for this cancer.